Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2930)	9/12/2013 8:34:13 AM
From: fred hayes	Read Replies (1) \| Respond to of 3202

I hope you had the right answer...

To: scaram(o)uche who wrote (2930)	9/12/2013 2:22:21 PM
From: quantman	Read Replies (1) \| Respond to of 3202

On a more serious note, I think it was a good presentation. Frankly, I was surprised at the near unbounded optimism of what the subgroup success means for other solid tumours. Rich Levy was quite good....and I hope they will present the data before next year's ASCO. I was also pleased to hear his bullish comments re the IDO inhibitor at the end of the Q&A, based on data he said had not been disclosed yet... I expect a deal for one of the JAK 1 inhibitors in inflamm with a large pharma, other than LLY, since the CMO pretty much ruled out LLY. When do you think NVS will start their phase 2 Ruxo combo trial for PC in Europe?